Integra LifeSciences Holdings (IART) - Total Liabilities
Based on the latest financial reports, Integra LifeSciences Holdings (IART) has total liabilities worth $2.54 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Integra LifeSciences Holdings annual equity growth to track the company's year-over-year net asset growth rate.
Integra LifeSciences Holdings - Total Liabilities Trend (1995–2025)
This chart illustrates how Integra LifeSciences Holdings's total liabilities have evolved over time, based on quarterly financial data. See Integra LifeSciences Holdings (IART) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Integra LifeSciences Holdings Competitors by Total Liabilities
The table below lists competitors of Integra LifeSciences Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongguan Eontec Co Ltd
SHE:300328
|
China | CN¥1.93 Billion |
|
Hunan Boyun New Materials Co Ltd
SHE:002297
|
China | CN¥970.26 Million |
|
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
|
China | CN¥1.40 Billion |
|
Yihai International Holding Ltd
F:YIR
|
Germany | €723.71 Million |
|
Genting Plantations Bhd
KLSE:2291
|
Malaysia | RM3.83 Billion |
|
Saha Pathana Inter-Holding PCL
BK:SPI
|
Thailand | ฿23.20 Billion |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥2.21 Billion |
|
Wuhan East Lake High Technology Group Co Ltd
SHG:600133
|
China | CN¥8.69 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Integra LifeSciences Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Integra LifeSciences Holdings worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integra LifeSciences Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integra LifeSciences Holdings (1995–2025)
The table below shows the annual total liabilities of Integra LifeSciences Holdings from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.56 Billion | +2.66% |
| 2024-12-31 | $2.49 Billion | +13.58% |
| 2023-12-31 | $2.19 Billion | +5.21% |
| 2022-12-31 | $2.09 Billion | -0.58% |
| 2021-12-31 | $2.10 Billion | -0.13% |
| 2020-12-31 | $2.10 Billion | +11.33% |
| 2019-12-31 | $1.89 Billion | +8.91% |
| 2018-12-31 | $1.73 Billion | -22.98% |
| 2017-12-31 | $2.25 Billion | +132.26% |
| 2016-12-31 | $968.29 Million | -5.37% |
| 2015-12-31 | $1.02 Billion | +17.04% |
| 2014-12-31 | $874.30 Million | +66.20% |
| 2013-12-31 | $526.05 Million | -18.55% |
| 2012-12-31 | $645.82 Million | -0.87% |
| 2011-12-31 | $651.47 Million | +25.93% |
| 2010-12-31 | $517.35 Million | +4.47% |
| 2009-12-31 | $495.22 Million | -27.62% |
| 2008-12-31 | $684.23 Million | +22.71% |
| 2007-12-31 | $557.58 Million | +75.64% |
| 2006-12-31 | $317.46 Million | +100.14% |
| 2005-12-31 | $158.61 Million | +6.53% |
| 2004-12-31 | $148.89 Million | +3.40% |
| 2003-12-31 | $144.00 Million | +431.92% |
| 2002-12-31 | $27.07 Million | +15.04% |
| 2001-12-31 | $23.53 Million | -28.11% |
| 2000-12-31 | $32.73 Million | +15.66% |
| 1999-12-31 | $28.30 Million | +757.58% |
| 1998-12-31 | $3.30 Million | +26.92% |
| 1997-12-31 | $2.60 Million | +13.04% |
| 1996-12-31 | $2.30 Million | +15.00% |
| 1995-12-31 | $2.00 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more